clec4a: a drug target and biomarker for the treatment of neurodegenerative diseases

Target Name: CLEC4A

NCBI ID: G50856

CLEC4A

clec4a: a drug target and biomarker for the treatment of neurodegenerative diseases

Introduction

Neurodegenerative diseases are a group of disorders that affect the nervous system and can result in progressive cognitive and motor function loss. These diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are often treated with drugs that aim to slow down or halt the progression of the disease. However, current treatments are often limited in their effectiveness and can have potential side effects. There is a need for new and better treatments that can specifically target the underlying causes of neurodegenerative diseases.

CLEC4A: a drug target and biomarker

CLEC4A is a protein that is expressed in the brain and has been shown to play a role in the development and progression of neurodegenerative diseases. It is a member of the elastin family, which is known for their ability to interact with various molecules in the brain. clec4a has been shown to interact with the protein tau and the neurotransmitter dopamine.

Clec4a has also been shown to be involved in the formation of neurofibrillary tangles, which are composed of abnormal aggregates of the protein tau. These tangles are thought to contribute to the progressive neurofibrillary changes that occur in neurodegenerative diseases. By targeting clec4a, researchers may be able to develop new treatments that specifically target the underlying causes of these diseases.

CLEC4A as a biomarker

In addition to its role as a drug target, clec4a has also been shown to be a potential biomarker for neurodegenerative diseases. clec4a levels have been shown to be elevated in the brains of individuals with neurodegenerative diseases, and lower levels have been seen in individuals without these diseases. This suggests that clec4a may be a useful diagnostic tool for neurodegenerative diseases.

Clec4a levels have also been shown to be correlated with the level of tau protein in the brain. This suggests that clec4a may be a useful biomarker for tracking the progression of neurodegenerative diseases.

Targeting clec4a

Research has shown that clec4a can be targeted with small molecules. By using a library of potential drugs that interact with clec4a, researchers have been able to identify compounds that are able to specifically bind to the protein and prevent its activity. These compounds have been shown to be effective in animal models of neurodegenerative diseases.

One potential approach to targeting clec4a is to use small molecules that specifically bind to clec4a's active site. This would allow for the development of drugs that can specifically inhibit clec4a's activity and potentially slow down or halt the progression of neurodegenerative diseases.

Conclusion

CLEC4A is a protein that has been shown to play a role in the development and progression of neurodegenerative diseases. As a drug target and biomarker, clec4a is an attractive target for researchers looking for new treatments for these diseases. By using small molecules that specifically bind to clec4a, researchers may be able to develop new treatments that specifically target the underlying causes of neurodegenerative diseases. Further research is needed to fully understand the role of clec4a in neurodegenerative diseases and to develop effective treatments.

Protein Name: C-type Lectin Domain Family 4 Member A

Functions: C-type lectin receptor that binds carbohydrates mannose and fucose but also weakly interacts with N-acetylglucosamine (GlcNAc) in a Ca(2+)-dependent manner (PubMed:27015765). Involved in regulating immune reactivity (PubMed:18258799, PubMed:10438934). Once triggered by antigen, it is internalized by clathrin-dependent endocytosis and delivers its antigenic cargo into the antigen presentation pathway resulting in cross-priming of CD8(+) T cells. This cross-presentation and cross-priming are enhanced by TLR7 and TLR8 agonists with increased expansion of the CD8(+) T cells, high production of IFNG and TNF with reduced levels of IL4, IL5 and IL13 (PubMed:18258799, PubMed:20530286). In plasmacytoid dendritic cells, inhibits TLR9-mediated IFNA and TNF production (PubMed:18258799). May be involved via its ITIM motif (immunoreceptor tyrosine-based inhibitory motifs) in the inhibition of B-cell-receptor-mediated calcium mobilization and protein tyrosine phosphorylation (PubMed:10438934)

The "CLEC4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLEC4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets